Petros’ ED Drug OTC Self-Selection Study Checks Nitrate Patient, ACNU Switch ‘Fail First’ Boxes

Study with 509 subjects conducted in Petros’ preparation of OTC switch application demonstrated 90.6% correct self-selection for participants using its web app technology and DFL and 57.3% correct by subjects using only DFL.

Petros Pharmaceuticals, Inc.’s overall strong results from a self-selection study featuring its digital app for OTC access to its Stendra (avanafil) erectile dysfunction drug include particularly strong accuracy by a key group of consumers, nitrate users.

The study with 509 subjects conducted in Petros’ preparation of an Rx-to-OTC switch application demonstrated 90.6% overall correct self-selection for...